David R Spencer

US Patent:

6758509, Jul 6, 2004

Filed:

May 20, 2003

Appl. No.:

10/441175

Inventors:

David C. Spencer - Houston TX 77091

International Classification:

B60R 504

US Classification:

296 376, 29610006

Abstract:

A pick-up bed space divider includes a device for removably positioning in a pick-up bed. The pick-up bed has a bottom wall, a pair of side walls, and a tailgate. The bottom wall has a pair of wheel wells. The device has a first panel having an upper edge, a bottom edge and a pair of side edges. The bottom edge is selectively abutted against the bottom wall and positioned adjacent to the wheel wells. A second panel has a back edge, a front edge, and a pair of lateral edges. A hinge is attached to and pivotally couples the back edge to the upper edge. The second panel has a width between the lateral edges that is greater than a width between the side walls. The second panel abuts an upper edge of the side walls and the tailgate when the second panel is in a horizontal position.

US Patent:

7404950, Jul 29, 2008

Filed:

Feb 18, 2004

Appl. No.:

10/781384

Inventors:

David Spencer - Houston TX, US
Brent Hanks - Houston TX, US
Kevin Slawin - Houston TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 48/00
C07H 21/04

US Classification:

424 9321, 424 931, 424 932, 536 231, 536 234, 514 44

Abstract:

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

US Patent:

8486693, Jul 16, 2013

Filed:

Sep 19, 2012

Appl. No.:

13/622501

Inventors:

Dongsu Park - Houston TX, US
David Spencer - Houston TX, US
Natalia Lapteva - Houston TX, US

Assignee:

Bellicum Pharmaceuticals, Inc. - Houston TX

International Classification:

C12N 5/00
C12N 5/07
C12N 5/0784
C12N 5/10

US Classification:

435325, 435355, 435362, 435363, 424 931, 424 9321

Abstract:

Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt. ” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt. ”.

US Patent:

20030144204, Jul 31, 2003

Filed:

Dec 19, 2002

Appl. No.:

10/324985

Inventors:

David Spencer - Houston TX, US

Assignee:

Baylor College of Medicine

International Classification:

A61K048/00
C07K014/705
A61K038/17
C07H021/04

US Classification:

514/012000, 514/044000, 530/350000, 536/023500, 435/320100, 435/325000

Abstract:

The present invention relates to the field of apoptosis and programmed cell-death. More particularly, it relates to expression vectors, pharmaceutical compositions and methods for inhibiting cell-death using the expression vectors and/or pharmaceutical compositions. Yet further, the present invention also relates to methods of using the expression vector to screen for additional regulators of an anti-apoptotic gene.

US Patent:

20040040047, Feb 26, 2004

Filed:

Sep 19, 2002

Appl. No.:

10/247019

Inventors:

David Spencer - Houston TX, US
Kevin Slawin - Houston TX, US

International Classification:

A01K067/00
A61K048/00
C12N015/00

US Classification:

800/008000, 514/044000, 435/320100

Abstract:

The present invention discloses artificial death switches (ADSs) based on chemically induced dimerization of the cysteine proteases, caspase-1 (ICE) and caspase-3 (YAMA). In both cases, aggregation of the target protein is achieved by a non-toxic, lipid-permeable, dimeric FK506 analog that binds to an attached FK506-binding protein (FKBP). The intracellular crosslinking of caspase-1 or caspase-3 is sufficient to trigger rapid apoptosis in a Bcl-xL-independent manner, suggesting that these conditional pro-apoptotic molecules can bypass intracellular checkpoint genes, like Bcl-xL, that limit apoptosis. Since these chimeric molecules are derived from autologous proteins, they should be non-immunogenic and thus ideal for long-lived gene therapy vectors. These properties should also make chemically-induced apoptosis (CIA) useful for developmental studies, for treating hyperproliferative disorders and for developing animal models to a wide variety of diseases.

US Patent:

20060194230, Aug 31, 2006

Filed:

Jan 25, 2006

Appl. No.:

11/339733

Inventors:

Jonathan Levitt - Houston TX, US
Kevin Slawin - Houston TX, US
Eduardo Canto - Houston TX, US
David Spencer - Houston TX, US
Michael Ittmann - Houston TX, US

Assignee:

BAYLOR COLLEGE OF MEDICINE - Houston TX

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435006000, 435007230

Abstract:

The present invention regards expression profiles of one or more nucleic acids indicative of the presence of, susceptibility to, and/or predicting response to therapy of benign prostatic hyperplasia (BPH) in an individual. The present invention identifies pathways not previously associated with BPH, therefore presenting novel diagnostic and therapeutic targets for the condition.

US Patent:

20080269160, Oct 30, 2008

Filed:

Jun 30, 2008

Appl. No.:

12/165360

Inventors:

David Spencer - Houston TX, US
Brent Hanks - Houston TX, US
Kevin Slawin - Houston TX, US

International Classification:

A61K 31/7088
A61P 37/04

US Classification:

514 44

Abstract:

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

US Patent:

20100152770, Jun 17, 2010

Filed:

Dec 15, 2009

Appl. No.:

12/638519

Inventors:

David Spencer - San Antonio TX, US

International Classification:

A61B 17/00

US Classification:

606203

Abstract:

A bleed out prevention system and method includes an adjustable length attachment belt assembly which is passed around the body of a human being suspected of having an injured or severed major blood vessel. The adjustable length attachment belt assembly positions a plunger plate assembly over a location where compressive force can be applied to a portion of the major blood vessel which has not been injured or severed. A compressive force application assembly then applies force which reduces the size of the lumen in the major blood vessel thereby restricting or stopping the flow of blood therethrough.